These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11471565)

  • 21. Therapeutic applications of catalytic antisense RNAs (ribozymes).
    Rossi JJ
    Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical characterization of an anti-tat ribozyme for therapeutic application.
    Wang L; Witherington C; King A; Gerlach WL; Carr A; Penny R; Cooper D; Symonds G; Sun LQ
    Hum Gene Ther; 1998 Jun; 9(9):1283-91. PubMed ID: 9650613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of HIV-1 replication and dimerization interference by dual inhibitory RNAs.
    Sánchez-Luque FJ; Reyes-Darias JA; Puerta-Fernández E; Berzal-Herranz A
    Molecules; 2010 Jul; 15(7):4757-72. PubMed ID: 20657391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression.
    Dropulić B; Lin NH; Martin MA; Jeang KT
    J Virol; 1992 Mar; 66(3):1432-41. PubMed ID: 1738200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy may restore immune systems.
    Bowersox J
    NIAID AIDS Agenda; 1997 Aug; ():8. PubMed ID: 11364613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.
    Lainé S; Scarborough RJ; Lévesque D; Didierlaurent L; Soye KJ; Mougel M; Perreault JP; Gatignol A
    RNA Biol; 2011; 8(2):343-53. PubMed ID: 21422817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and evaluation of clinically relevant SOFA-HDV ribozymes targeting HIV RNA.
    Scarborough RJ; Lévesque MV; Perreault JP; Gatignol A
    Methods Mol Biol; 2014; 1103():31-43. PubMed ID: 24318884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
    Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
    Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Technology evaluation: HIV ribozyme gene therapy, Gene Shears Pty Ltd.
    de Feyter R; Li P
    Curr Opin Mol Ther; 2000 Jun; 2(3):332-5. PubMed ID: 11249628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV chemotherapy.
    Richman DD
    Nature; 2001 Apr; 410(6831):995-1001. PubMed ID: 11309630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective inhibition of human immunodeficiency virus 1 replication by engineered RNase P ribozyme.
    Zeng W; Chen YC; Bai Y; Trang P; Vu GP; Lu S; Wu J; Liu F
    PLoS One; 2012; 7(12):e51855. PubMed ID: 23300569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.
    Wong-Staal F; Poeschla EM; Looney DJ
    Hum Gene Ther; 1998 Nov; 9(16):2407-25. PubMed ID: 9829540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oligonucleotides as inhibitors of human immunodeficiency virus.
    Field AK
    Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach.
    Waninger S; Kuhen K; Hu X; Chatterton JE; Wong-Staal F; Tang H
    J Virol; 2004 Dec; 78(23):12829-37. PubMed ID: 15542635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo transduction and expansion of CD4+ lymphocytes from HIV + donors: prelude to a ribozyme gene therapy trial.
    Leavitt MC; Yu M; Wong-Staal F; Looney DJ
    Gene Ther; 1996 Jul; 3(7):599-606. PubMed ID: 8818647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
    Ramezani A; Ding SF; Joshi S
    Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection.
    Westaway SK; Cagnon L; Chang Z; Li S; Li H; Larson GP; Zaia JA; Rossi JJ
    Antisense Nucleic Acid Drug Dev; 1998 Jun; 8(3):185-97. PubMed ID: 9669656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.